Belgium's Argenx Advances On More Positive Efgartigimod Data
Filing Imminent For Promising Myasthenia Gravis Therapy
Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.
